ADC Drug Efficacy In Vitro & In Vivo
Delivering potent toxins to targeted cancer cells
Antibody-drug conjugates (ADCs) are an important class of therapeutics for the treatment of cancer. ADCs are potent cytotoxic agents by linking cytotoxic small molecules to monoclonal antibodies (mAbs) that directly recognize a specific antigen on tumor cell surface. Compared with the therapeutic mAbs, ADCs-derived monoclonal antibody is conjugated with cytotoxic agents which can deliver potent cellular toxins to targeted cancer cells specifically.
We started ADC non-clinical research in 2014. As of the end of 2022, We has successfully assisted in the clinical approval of 13 ADC drugs by NMPA and/or FDA and has more than 10 ADC projects under development. Up to now, Medicilon has undertaken more than 100 major IND application biopharmaceutical projects, including monoclonal antibodies, double antibodies, polyclonal antibodies, ADCs, viral vaccines and fusion proteins.